The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Wilens, T. E.
* Articles by Parekh, A.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Wilens, T. E.
* Articles by Parekh, A.
Related Collections
* Neurotransmitters
* Attention Deficit Hyperactivity Disorder
* Antidepressants
* Other Somatic Therapy
Am J Psychiatry 158:282-288, February 2001
© 2001 American Psychiatric Association


Article

A Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults

Timothy E. Wilens, M.D., Thomas J. Spencer, M.D., Joseph Biederman, M.D., Kristine Girard, M.D., Robert Doyle, M.D., Jefferson Prince, M.D., David Polisner, B.A., Ramon Solhkhah, M.D., Sharyn Comeau, M.D., Michael C. Monuteaux, B.A., and Asha Parekh, M.D.

OBJECTIVE: Despite the increasing recognition of attention deficit hyperactivity disorder (ADHD) in adults, there is a paucity of controlled pharmacological trials demonstrating the effectiveness of compounds used in treatment, particularly nonstimulants. The authors report results from a controlled investigation to determine the anti-ADHD efficacy of bupropion in adult patients with DSM-IV ADHD. METHOD: This was a double-blind, placebo-controlled, randomized, parallel, 6-week trial comparing patients receiving sustained-release bupropion (up to 200 mg b.i.d.) (N=21) to patients receiving placebo (N=19). The authors used standardized structured psychiatric instruments for diagnosis of ADHD. To measure improvement, they used separate assessments of ADHD, depression, and anxiety symptoms at baseline and each weekly visit. RESULTS: Of the 40 subjects (55% male) enrolled in the study, 38 completed the study. Bupropion treatment was associated with a significant change in ADHD symptoms at the week-6 endpoint (42% reduction), which exceeded the effects of placebo (24% reduction). In analyses using a cutoff of 30% or better reduction to denote response, 76% of the subjects receiving bupropion improved, compared to 37% of the subjects receiving placebo. Similarly, in analyses using Clinical Global Impression scale scores, 52% of the subjects receiving bupropion reported being "much improved" to "very improved," compared to 11% of the subjects receiving placebo. CONCLUSIONS: These results indicate a clinically and statistically significant effect of bupropion in improving ADHD in adults. The results suggest a therapeutic role for bupropion in the armamentarium of agents for ADHD in adults, while further validating the continuity of pharmacological responsivity of ADHD across the lifespan.




This article has been cited by other articles:


Home page
J Atten DisordHome page
M. A. Davidson
Literature Review: ADHD in Adults: A Review of the Literature
J Atten Disord, May 1, 2008; 11(6): 628 - 641.
[Abstract] [PDF]


Home page
APPI Online CMEHome page
References
PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2.
[Full Text]


Home page
FocusHome page
T. R. Kosten and T. A. Kosten
New Medication Strategies for Comorbid Substance Use and Bipolar Affective Disorders
Focus, January 1, 2007; 5(2): 262 - 269.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
D. J. Nutt, K. Fone, P. Asherson, D. Bramble, P. Hill, K. Matthews, K. A. Morris, P. Santosh, E. Sonuga-Barke, E. Taylor, et al.
Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology
J Psychopharmacol, January 1, 2007; 21(1): 10 - 41.
[Abstract] [PDF]


Home page
Journal of Pharmacy PracticeHome page
D. A. Sherwood and J. A. Rey
Pharmacological Agents for the Treatment of Adult Attention Deficit Hyperactivity Disorder: A Review of the Literature
Journal of Pharmacy Practice, December 1, 2006; 19(6): 336 - 341.
[Abstract] [PDF]


Home page
Arch Gen PsychiatryHome page
J. Poling, A. Oliveto, N. Petry, M. Sofuoglu, K. Gonsai, G. Gonzalez, B. Martell, and T. R. Kosten
Six-Month Trial of Bupropion With Contingency Management for Cocaine Dependence in a Methadone-Maintained Population
Arch Gen Psychiatry, February 1, 2006; 63(2): 219 - 228.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
N. N. Bumpus, C. Sridar, U. M. Kent, and P. F. Hollenberg
THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATION
Drug Metab. Dispos., June 1, 2005; 33(6): 795 - 802.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
J. J. McGough and R. A. Barkley
Diagnostic Controversies in Adult Attention Deficit Hyperactivity Disorder
Am J Psychiatry, November 1, 2004; 161(11): 1948 - 1956.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
T. E. Wilens, S. V. Faraone, and J. Biederman
Attention-Deficit/Hyperactivity Disorder in Adults
JAMA, August 4, 2004; 292(5): 619 - 623.
[Full Text] [PDF]


Home page
Adv. Psychiatr. Treat.Home page
M. Zwi and A. York
Attention-deficit hyperactivity disorder in adults: validity unknown
Adv. Psychiatr. Treat., July 1, 2004; 10(4): 248 - 256.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
I. D. Maidment
The Use of Antidepressants to Treat Attention Deficit Hyperactivity Disorder in Adults
J Psychopharmacol, September 1, 2003; 17(3): 332 - 336.
[Abstract] [PDF]


Home page
Intervention in School and ClinicHome page
V. L. Austin
Pharmacological Interventions for Students with ADD
Intervention in School and Clinic, May 1, 2003; 38(5): 289 - 296.
[Abstract] [PDF]


Home page
CMAJHome page
M. Weiss and C. Murray
Assessment and management of attention-deficit hyperactivity disorder in adults
Can. Med. Assoc. J., March 18, 2003; 168(6): 715 - 722.
[Abstract] [Full Text] [PDF]


Home page
PsychosomaticsHome page
A. H. Clayton and J. Kaltsounis-Puckett
Combination Therapy in the Treatment of Major Depressive Disorder Complicated by Fibromyalgia and Menopause
Psychosomatics, December 1, 2002; 43(6): 491 - 493.
[Full Text] [PDF]


Home page
Evid. Based Ment. HealthHome page
J C Ferre and D. Nutt
Bupropion improved symptoms in adults with attention deficit hyperactivity disorder
Evid. Based Ment. Health, August 1, 2001; 4(3): 92 - 92.
[Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
T. J. Spencer, J. Biederman, S. Faraone, E. Mick, B. Coffey, D. Geller, J. Kagan, S. K. Bearman, and T. Wilens
Impact of Tic Disorders on ADHD Outcome Across the Life Cycle: Findings From a Large Group of Adults With and Without ADHD
Am J Psychiatry, April 1, 2001; 158(4): 611 - 617.
[Abstract] [Full Text]


Home page
J Atten DisordHome page
T. E. Wilens, T. J. Spencer, and J. Biederman
A review of the pharmacotherapy of adults with Attention-Deficit/ Hyperactivity Disorder
J Atten Disord, January 1, 2001; 5(4): 189 - 202.
[Abstract] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2001 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org